Transforming growth factor-b (TGF-b) is perhaps the most potent endogenous negative regulator of hematopoiesis. The intracellular signaling events mediating the effects of TGF-b are multiple, involving extensive crosstalk between Smad-dependent and MAP-kinase-dependent pathways. We are only beginning to understand the importance of the balance between these cascades as a determinant of the response to TGF-b, and have yet to determine the roles that disruption in TGF-b signaling pathways might play in leukemogenesis. This review summarizes current knowledge regarding the function of TGF-b in normal and malignant hematopoiesis. The principal observations made by gene targeting studies in mice are reviewed, with an emphasis on how a disruption of this pathway in vivo can affect blood cell development and immune homeostasis. We overview genetic alterations that lead to impaired TGF-b signaling in hematopoietic neoplasms, including the suppression of Smad-dependent transcriptional responses by oncoproteins such as Tax and Evi-1, and fusion proteins such as AML1/ETO. We also consider mutations in genes encoding components of the core cell cycle machinery, such as p27 Kip1 and p15
Introduction
The transforming growth factors-bs (TGF-bs) form a group of highly homologous secreted polypeptide signaling molecules that belong to a large superfamily of factors that control growth, differentiation, and apoptosis of cells. TGF-b inhibits the proliferation of cells within the epithelial, endothelial, and hematopoietic lineages, regulates the differentiation of immune, neuronal, mesenchymal, and epithelial cell types, initiates apoptosis in a context-dependent manner, and plays a role in the maintenance of chromosomal stability. [1] [2] [3] [4] TGF-b binds to a heteromeric cell-surface complex of type I (TbRI) and type II (TbRII) serine/threonine kinase receptors. 5 Following ligandbinding, TbRII recruits and activates TbRI, which in turn phosphorylates downstream targets. These include the TbRIactivated Smad proteins, which are phosphorylated on their Cterminus and then translocate to the nucleus in complex with the common mediator Smad4 (co-Smad) to regulate transcription of target genes. 6, 7 The principal receptor-activated Smads (R-Smads) involved in signaling from TGF-b receptors are Smad2 and Smad3. In the nucleus, Smad proteins can bind directly to their cognate DNA-binding sites and/or interact with an increasing number of transcription factors, transcriptional coactivators, or transcriptional repressors. 8, 9 The activity of this pathway is further modulated by a class of inhibitory-Smads that form stable complexes with the activated receptors and inhibit signaling by preventing access and phosphorylation of the R-Smads. Thus, the TGF-b response is negatively regulated by both Smad6 and Smad7, which can inhibit the TGF-b-induced activation of either Smad2 or Smad3. 10 Recent studies have shown that there is extensive crosstalk between the Smad pathway and other signaling pathways. TGF-b can directly activate the ERK, p38, and c-Jun N-terminal kinase (JNK) signaling pathways. 11, 12 There is considerable crosstalk between the TGF-b-Smad signaling pathway and the MAPK signaling cascades. [13] [14] [15] [16] A novel MAPKKK termed TGF-b-activating kinase (TAK1) participates in signal transduction of TGF-b1 and has been shown to activate both the p38 pathway, 17, 18 and the JNK pathway ( Figure 1) . 12, 19, 20 The role of TGF-b in hematopoiesis TGF-b plays an important role in regulating the balance between proliferation and differentiation in hematopoietic cells. [21] [22] [23] [24] These activities are often context dependent, influenced by the collective input from a multitude of soluble factors and matrixassociated proteins that orchestrate the complex events associated with blood cell development. TGF-b1 is known to influence both the proliferation and differentiation of the uncommitted stem cell precursors and of myeloid progenitors. 25, 26 TGF-b can modulate the response of progenitors to stem cell factor (SCF) and suppress expression of the SCF receptor c-kit. [27] [28] [29] [30] Relative to other factors acting on hematopoietic precursors, TGF-b is widely considered the most potent inhibitor of cell cycle progression in committed progenitors, and will suppress in vitro colony formation in cytokine supplemented suspension cultures. There is abundant evidence that autocrine production of TGF-b by hematopoietic stem cells acts to maintain their quiescence. 31 This effect may be mediated by several events that are activated downstream of the TGF-b receptor. This includes the transcriptional repression of the proto-oncogene c-myc, 32 downmodulation of the expression and activities of G1 and G2 cyclin-dependent kinase (CDK) and cyclins, [33] [34] [35] and activation of the genes encoding p15
INK4b
, [36] [37] [38] [39] [40] p21 Cip1 , [41] [42] [43] [44] [45] or p27 Kip1 that encode CDK inhibitors ( Figure 1 ). [46] [47] [48] Several studies have implicated that TGF-b may act through mechanisms involving the cip/kip inhibitors of CDKs (p21 Cip1 / p27 Kip1 ). [49] [50] [51] However, there is also data supporting a model whereby TGF-b can exert growth arrest independent of this class of cell cycle regulators. 52 It is also known that TGF-b can directly control the expression of the stem cell antigen CD34, 53, 54 and in specific contexts, can prohibit differentiation via mechanisms not linked to cell cycle arrest. 48, 54 The transcriptional modulation of CD34 expression by TGF-b is associated with nuclear translocation of receptor-activated Smad2, but has also been linked to MAP kinase pathways as there is an association with downmodulation of p38 phosphorylation, as well as activation of the TAK-1. 54 Such observations highlight the involvement of divergent downstream intracellular intermediates in the TGF-b pathway, and illustrate how the balance of these signals is what may ultimately determine the differentiation of progenitors in response to extracellular signals such as TGF-b.
Murine models implicate TGF-b as an important regulator of hematopoiesis
The relevance of these activities is supported by the phenotypes of a number of murine models in which components of the TGF-b signaling pathway have been disrupted. The first example was provided by the Tgf-b1 À/À mouse, in which there is a significant increase in numbers of circulating granulocytes, monocytes, and platelets. 55, 56 Studies of isolated populations of cells from the Tgf-b1 À/À mouse have also implicated autocrine production of TGF-b1 in the regulation of hematopoietic progenitors. Hematopoietic stem cell (HSC) lines derived from marrow of adult Tgf-b1 À/À mice exhibit enhanced colonyforming efficiency in response to combinations of IL-3, IL-6, and G-CSF, as well as spontaneous differentiation of progenitors into megakaryoctyes (unpublished observations). These findings have been corroborated by a new model system in which the TGF-b pathway is disrupted in hematopoietic progenitors via in vitro transduction with a retroviral vector expressing a dominant-negative-acting TGF-b type II receptor (DN-TbRII) in a bicistronic vector with GFP. 57 In mice reconstituted with the transduced HSC, the bone marrow retains greater than 95% GFP + cells at 6 months, and ultimately the mice develop a severe myeloid hyperplasia and anemia. These mice also demonstrate a skewing of T cells to a memory phenotype, but the myeloid expansion is the most dramatic phenotype and is responsible for their demise. In a similar model involving a Cre-recombinase-mediated deletion of a floxed TbRII allele, mice reconstituted with TbRII À/À HSC go on to develop the aggressive autoimmune manifestations typical of the Tgf-b1 À/À , but no increase in proliferation or number of individual myeloid elements were described. 58 A similar phenotype has been described in mice expressing the DN-TbRII under the control of a T-cell-specific promoter. 59, 60 These models implicate an important function for TGF-b in maintaining hematopoietic and immune cell homeostasis and in preventing autoimmune disease, but as yet have not established a direct link between disruption of TGF-b signaling and leukemogenesis. Ultimately, comparisons of the outcomes in models taking these distinct approaches will help to clarify the principle activities of TGF-b in the early HSC and in their committed progenitors.
Mutational inactivation of the TGF-b signaling pathway uncommon in leukemia
Given the above observations, it is logical to predict that any functional impairment in the TGF-b pathway may predispose to leukemogenesis. There is abundant data regarding the effects of TGF-b on leukemic cells lines, which range from inhibition of proliferation and induction of differentiation, to altered expression of adhesion molecules and cytokine receptors, and the induction of apoptosis. [61] [62] [63] In general, these studies suggest that, in most hematopoietic malignancies, essential components of the TGF-b signaling pathway are indeed expressed and can at a minimum transduce transcriptional responses, even in the absence of the ability to induce a complete growth arrest or initiate an apoptotic response.
The disruption of TGF-b1 signaling, either via mutational inactivation of components of the signaling pathway, or by downmodulation of their expression, is known to play an important role in malignant transformation. Many epithelial neoplasms, including colon, breast, pancreatic, and hepatocellular carcinoma have been characterized by alterations in TGF-b pathway genes, including Smad2, Smad4, and TbRII. In the realm of hematopoietic tumors, there are anecdotal reports of sporadic mutations in both TbRI and TbRII occurring in lymphoid neoplasms. These include a single report of a mutation in the TbRII gene in gastric lymphoma, as well as a report of a deletion in the TbRI gene and a dominant-negativeacting mutant of TbRII each found in cutaneous T-cell lymphoma. 64, 65 The loss of TGF-b receptor expression at the cell surface has been reported in lymphoid neoplasms and EBVtransformed B lymphoblastoid cell lines. 66 While the mechanisms leading to the downmodulation of receptor expression are not well defined, it is clear that they are not the consequence of mutational inactivation of genes encoding the TGF-b signaling receptors.
TbRII coding region microsatellite mutations characteristic of defective DNA mismatch repair (MMR) have been reported in primary samples of human T-cell lymphoblastic lymphoma (T-LBL)/T-cell acute lymphoblastic leukemia (T-ALL), 67 implicating TbRII coding region microsatellite mutations in the pathogenesis of human T-LBL/ALL. Mutations in TbRII associated with microsatellite instability (replication error phenotype, RER+) was also observed in 20% of cell lines derived from hematologic malignancies such as T-ALL and pre-B-ALL cell lines. 68 However, microsatellite instability affecting the TbRII gene is very uncommon in freshly isolated ALL, suggesting that mutations in the DNA resulting from MMR defects are likely to be selected for during the establishment of cell lines.
It has been proposed that genomic instability plays a role in the disease progression of chronic myeloid leukemia (CML). However, alterations of the microsatellite regions in the TbRII gene are not involved in the progression of CML. Analysis of TbRII mRNA expression with comparison of cells from the chronic, accelerated and blast phases of CML, showed no change in TbRII transcript levels during disease progression. However, during each phase of the disease, low levels of TbRII were detected when compared with the hematopoietic cells of normal donors. 69 The decreased expression of TbRII in CML raises the possibility that transcriptional repression of TbRII may play a role in the initiation and/or maintenance of the disease state. A decrease of TbRII was also observed in B-cell chronic lymphocytic leukemia (B-CLL). B lymphocytes isolated from the peripheral blood of B-CLL patients were resistant to TGF-b growth inhibitory activity in 30% of the cases. A strong correlation was found between the response of leukemic B cells to TGF-b and their expression of TGF-b receptors, consistent with the hypothesis that TGF-b acts as a negative regulator of B lymphocyte proliferation and blocks progression in CLL. Thus, the loss of responsiveness to TGF-b secondary to decreased TGF-b receptor expression might provide a selective advantage to B-CLL lymphocytes.
Mutations in Smad genes are also seemingly rare in hematopoietic tumors. In a single report, two distinct mutations in Smad4 were described in myeloid leukemia. 70 These included a missense mutation in the MH1 domain and a frame-shift mutation in the MH2 domain leading to premature termination, and each disrupts transcriptional activity. In general, it would appear that the disruption of TGF-b responsiveness in hematopoietic neoplasms is more commonly the consequence of events that fall into two distinct categories: (a) altered expression of coactivators or corepressors involved in TGF-b-induced transcriptional responses and (b) loss/disruption of TGF-b target gene expression (Figures 1 and 2) .
In the first category, there are a number of coactivators that have been altered in the context of leukemias, including CBP, p300, 71 and AML1. 72, 73 The most frequent translocation found in de novo adult acute myeloid leukemia, t(8;21), results in the formation of the AML1/ETO chimeric transcription factor. The N-terminal region of the AML protein retained in this newly formed protein contains a region of homology with FAST proteins, which are known to cooperate with Smads to regulate the cellular response to TGF-b. It has been reported that the physical association of AML1 and AML1/ETO with Smads occurs via their runt homology domain. More importantly, while AML1B cooperates with Smads to induce transcription in response to TGF-b, the AML1/ETO fusion represses basal transcription of TGF-b-responsive genes and ablates their induction in response to exogenous TGF-b. 74 This is consistent with the concept that this chimeric molecule changes the function of AML1 from a context-dependent transcriptional activator to a repressor. The implication that the expression of this novel protein might alter the response to normal environmental signals that signal for differentiation is supported by studies in which expression of AML/ETO blocks differentiation in response to specific stimuli, including the combination of vitamin D3 and TGF-b. 75 In a similar fashion, the oncoprotein Evi-1 has been implicated in the abrogation of TGF-b responses in myeloid leukemia. [76] [77] [78] [79] [80] Evi-1 is often highly overexpressed in acute myeloid leukemia and myelodysplastic syndromes (MDS), and can directly interact with the transcriptional corepressor CtBP to repress TGF-b signaling. 76 The chimeric AML/EVI-1 produced by the t(3;21) translocation can abrogate the inhibition of myeloid cell proliferation in response to TGF-b, 79 in a manner that involves direct interaction of Smad3, thereby inhibiting its activity. There is a region of homology between the N-terminal binding domain of AML1 and the Smad interacting domains in FAST1 and FAST2 that appear to be responsible for these effects.
In the category of TGF-b target genes most likely to be involved in leukemogenesis, components of the cell cycle machinery are clearly the most relevant. In early G1, the downmodulation of c-myc is a primary response to TGF-b, 81 and is an effect that is mediated in part by a transcriptional complex of Smad3/E2F/DP-1 and the corepressor p107, acting directly on the c-myc promoter. 82 Oncoproteins such as c-ski, Evi-1, E1A, and Tax can alter Smad3 function and stability, and consequently abrogate the inhibitory effect of TGF-b on c-myc. [83] [84] [85] The repression of c-myc by TGF-b can also be abrogated as a consequence of activation of the lymphoid enhancer factor (LEF) via its interaction with the LEF/TCFresponsive element in the c-myc promoter. 86 While b-catenin can activate transcription of c-myc by binding to this element, it can be dissociated by TGF-b treatment, unless LEF-1 is also bound to this site. Thus the enhanced expression of LEF-1 in various malignancies, including colon cancer, 87 might confer resistance to TGF-b via ablation of c-myc regulation by this cytokine. The deregulation of c-myc may also be a consequence of chromosomal rearrangements, as in Burkitt's lymphoma where the classic 8; 14 translocation places c-myc under the control of the immunoglobulin promoter, thereby eliminating TGF-b-responsive elements. Thus multiple mechanisms can dissociate TGF-b response from repression of c-myc, and may thereby be an important step in leukemogenesis.
Later in G1, the ability of TGF-b to modulate the expression and activity of inhibitors of the cyclin-dependent kinases is thought to be a critical step in prohibiting the progression to S phase. Among this class of inhibitors, p15 INK4B , p21
Cip1
, and p27
Kip1 have all been shown to be effectors of TGF-b-induced cell cycle arrest in various contexts. [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] Alterations in the genes encoding these proteins are also commonly associated with leukemogenesis. For example, the p27 Kip1 gene (CDKN1B) is assigned to chromosome 12p12, and this region is frequently Mechanism of signaling by TGF-b. TGF-bs bind and activate TGF-b receptor complex. Activated type I receptor phosphorylates a R-Smad at a conserved SSXS motif at the carboxyl terminus of the protein, which assemble into heteromeric complexes with the coSmad4. Smad complexes translocate to the nucleus where they control transcription of target genes cooperatively with other transcription factors, coactivators and corepressors. Target gene expression and cellular response are also modulated by TGF-b via activation of PI3K and various MAPK pathways.
Figure 2
Molecular events associated with leukemogenesis can block the ability of TGF-b to induce growth arrest. Altered expression or mutational inactivation of components of the cell cycle machinery (*), including c-myc, p15INK4, p21
Cip1
Kip1 can result in TGF-b resistance in hematopoietic cells. Smad3 is the putative target of multiple oncoproteins that functionally inactivate TGF-b signaling via this intermediate. altered in pediatric ALL, typically as a result of translocations and chromosomal deletions. 88 In one series, hemizygous deletions of p27 Kip1 were found in over 80% of primary ALL specimens from patients known to have abnormalities at the 12p locus. Homozygous inactivation of both alleles has been described in two cases of childhood ALL, including one instance involving a germline mutation with subsequent biallelic inactivation in the malignant lymphoblasts. 89 The homozygous deletion of the p27 Kip1 gene has also been reported in nonHodgkin's lymphoma (NHL) and adult T-cell leukemia (ATL). 90 These observations not only highlight the importance of this inhibitor of the cyclinE/cdk2 complex in the suppression of malignant transformation in hematopoietic cells, but also implicate the downmodulation of p27
Kip1 activity as a potential mechanism for abrogating the tumor suppressor effects of the TGF-b pathway.
The expression of INK4 family members is also commonly altered in hematopoietic malignancies. In most instances, this involves inactivation of p16
INK4A and p15 INK4B due to hypermethylation of CpG islands in their promoters or by deletions in the 9p21 region, frequently involving all three genes (reviewed in Kruz et al 91 ). Hypermethylation of the p15 INK4B promoter occurs most frequently in AML, found in over 70% of the cases, and in at least 40% of MDSs as well. Hypermethylation of the p15 INK4B promoter has also been found in over one-third of the cases of T-ALL and pre-B-ALL, in which deletions of both the INK4A and INK4B locus are found with a similar frequency. Aberrant methylation of this promoter is also frequently responsible for decreased expression of p15 in patients with MDS. TGF-b treatment fails to induce p15 expression in isolated CD34 + progenitors from MDS patients, and it is unable to induce G1 arrest and normal megakaryocytic differentiation in these progenitors. Thus, p15 may represent an important target gene, as loss of p15 expression has an impact on the TGF-b response, in a manner dependent on the lineage and state of differentiation of the cell.
Loss of TGF-b responsiveness and increased expression of TGF-b1 in human T-cell leukemia virus type I-infected T-cell leukemia
Human T-cell lymphotropic virus type I (HTLV-I) has been associated with an adult form of T-cell leukemia as well as tropical spastic paraparesis, a neurodegenerative disease. [92] [93] [94] The HTLV-I oncoprotein Tax is implicated in the various clinical manifestations associated with infection by HTLV-I, including an aggressive and fatal T-cell malignancy. 95 Tax is known to modulate cellular proliferative responses through two broad mechanisms. [96] [97] [98] [99] First, Tax directly targets specific transcriptional regulators including E2F, CREB, NFkB, SRF, Ikb, and CBP/P300. The regulation of E2F is a key target for oncoviruses. Second, in addition to transcriptional regulation, Tax modifies cell cycle regulators, primarily by affecting inhibitors of CDKs. Tax binds to and inactivates the p16
INK4A protein, which belongs to the INK4 family of CDK inhibitors, 100 thus resulting in the activation of CDK4. This effect of Tax relieves cells from p16
INK4A -induced growth arrest. HTLV-I-infected T-cell lines became resistant to TGF-b growth inhibitory activity. 101 Given the numerous studies that have documented that loss of TGF-b signaling promotes tumor formation, the development of TGF-b resistance may be an important mechanism underlying the oncogenic activity of the Tax protein.
Recent studies suggest that Tax may inhibit TGF-b transcription activity through several different mechanisms. [102] [103] [104] Tax and Smad are known to interact with CBP/p300 for the potentiation of their transcriptional activities. 102, 103 Tax inhibits TGF-b signaling, in part, by competitive interactions with both Smad proteins and p300. Tax also binds to Smad2, Smad3, and Smad4 directly and prevents binding of the Smad complex to its target sequence, thereafter inhibits TGF-b signal transduction. 103 Another study has shown that Tax induces JNK activity and c-Jun phosphorylation, leading to the preferential formation of Smad3/c-Jun complexes, thereby abrogating Smad3 DNA binding. 104 These results unequivocally suggest that the inhibition of TGF-b signaling by Tax may underlie HTLV-1-associated leukemogenesis.
Fresh leukemic cells from ATL patients have also been shown to constitutively produce high levels of TGF-b1 mRNA and secrete TGF-b1 into the culture medium. This effect is mediated by the activity of the HTLV-I Tax protein on the TGF-b1 promoter. 105 Tumors from transgenic mice carrying the HTLV-I tax gene and other tissues, such as submaxillary glands and skeletal muscle, which express high levels of Tax mRNA, selectively express high levels of TGF-b1 mRNA and protein. 106 T-cell proliferation is potently suppressed by TGF-b1 during the G1 phase of the cell cycle. TGF-b produced by the leukemic clone has the capacity to act on normal cells within the microenvironment, impairing cytolytic T lymphocyte activity, enhancing angiogenesis, and stimulating matrix protein production. Thus, in the context of HTLV-1-associated leukemogenesis, the increased secretion of the TGF-b1 coupled with a decreased responsiveness of the HTLV-I-infected cells to this cytokine tips the balance in favor of the pro-oncogenic activities of TGF-b.
Perspectives
The expression of receptors for TGF-b on primitive hematopoietic progenitors, and throughout all stages of their maturation and development, suggests a broad role for this cytokine in modulating the proliferation and differentiation of blood cells. This view is strongly supported by collective data from models that involve targeted and conditional disruption of TGF-b signaling in hematopoietic cells in vivo. These studies portray TGF-b as a critical 'brake', opposing the many positive factors that accelerate both the proliferative expansion and activation of cells in both the myeloid and lymphoid lineages. Although these murine models have not established a clear link between leukemogenesis and alterations in TGF-b signaling, the frequency of genetic alterations affecting this pathway, either directly or indirectly, suggest that it is a key target in the process of leukemogenesis. One can interpret these findings to suggest that disruption of TGF-b is not in itself sufficient to initiate malignant transformation, yet the loss of a TGF-b response may be a critical second step that contributes significantly to progression. Thus the aim of future studies should be to focus on the collaboration of specific signaling pathways with the TGF-b pathway and the mechanisms by which they suppress tumorigenesis. Based on the current data, it will clearly be important to place an emphasis on developing novel agents that can activate TGF-b signaling or modulate the resistance to this cytokine. Such compounds will have a strong potential for translation into both chemopreventive and therapeutic strategies for the management of leukemia.
